Clofarabine in Adult Patients With Advanced Solid Tumors

Inclusion Criteria: * Have a pathologic diagnosis of advanced solid tumors * After MTD is established, patients must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria * Be greater than or equal to 18 years old * Not eligible for therapy of higher curative potential * Have a Karnofsky Performance Status (KPS) greater than or equal to 70 * Have an estimated life expectancy of greater than or equal to 12 weeks * Have a negative serum or urine pregnancy test within 7 days of study enrollment (if patient is a female of childbearing potential) * Male and female patients who are fertile must agree to use an effective barrier method of birth control (latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy * Sign a written informed consent form * Able to comply with study procedures and follow-up examinations * Have adequate organ function as indicated by the following laboratory values, obtained within 2 weeks prior to registration: ANC: greater than or equal to 1.5 × 10 9th/L; Platelets: greater than or equal to 100 × 10 9th/L; Serum bilirubin: less than 2.0 mg/dL; AST and ALT: less than 3 x ULN (Institutional Upper Limit of Normal) without liver involvement OR less than 5 x ULN(\*) with liver involvement; Serum creatinine: less than 2.0 mg/dL; Echocardiogram shortening fraction: greater than or equal to 28%(Not on pharmacologic support); or Ejection fraction greater than or equal to 50% (Not on pharmacologic support). Exclusion Criteria: * Received previous treatment with clofarabine. * Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment. * Prior malignancy with less than a 2-year disease-free interval, except for adequately treated basal cell or squamous cell skin cancer; or in situ cancer of the cervix. * Are pregnant or lactating. * Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up. * Have received any chemotherapy, major surgery, or irradiation, whether conventional or investigational, \< 4 weeks before enrollment in this study (6 weeks for mitomycin-C or nitrosourea) and/or have not recovered from acute toxicities of all previous therapy prior to enrollment. * Have any other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study (eg, uncontrolled severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, etc.). * Have received prior radiation therapy to greater than or equal to 25% of the bone marrow (eg, no whole pelvic irradiation is allowed) and have not recovered from the acute side effects of radiotherapy. * Have received prior radiation therapy to the mediastinal region. * Have a broncho-alveolar pattern evident on chest x-ray. * Have symptomatic or untreated central nervous system (CNS) metastases.